once daily glp 1 A new chapter in GLP-1 treatment is here. Meet Foundayo™ by Eli Lilly, the first FDA-approved oral GLP-1, designed to support weight loss through a convenient once-daily approach. Prescription-only treatment, with instant A New Option in Weight
Description
Ozempic vs Zepbound compared head-to-head: the SURMOUNT-5 trial shows tirzepatide (20.2%) beats semaglutide (13.7%) for weight loss
Suggested Caption: On November 26, 2024, the Centers for Medicare &
Loss of muscle mass and strength not only impairs mobility and quality of life, but also worsens insulin resistance, accelerates cardiometabolic decline and increases mortality risk
One key distinction she highlighted is that tirzepatide acts on two hormone pathways, GLP-1 and GIP, which may make it more effective for some people in terms of fat loss, metabolism, and insulin resistance
